Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Total Liabilities came in at $314.8 million in Q1 2026, down 15.23% YoY from $371.3 million in Q1 2025, and down 8.31% on a QoQ basis from $343.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Total Liabilities data on file, last reported at $314.8 million in Q1 2026.
- Quarterly Total Liabilities fell 15.23% year-over-year to $314.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.8 million (down 15.23% YoY) and the FY2025 annual result came in at $343.3 million, down 17.05% from the prior year.
- Total Liabilities fell to $314.8 million in Q1 2026, from $343.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $413.8 million in Q4 2024 to a low of $156.7 million in Q1 2024.
- A 5-year average of $260.1 million and a median of $223.5 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 324.89% — and 2024, when it dropped 20.54%.
- Tracing RXRX's Total Liabilities over 5 years: stood at $215.5 million in 2022, then declined by 11.7% to $190.3 million in 2023, then surged by 117.5% to $413.8 million in 2024, then declined by 17.05% to $343.3 million in 2025, then declined by 8.31% to $314.8 million in 2026.
- The last three Total Liabilities figures came in at $314.8 million (Q1 2026), $343.3 million (Q4 2025), and $352.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 297.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 297.67 Mn |
| Mar 31, 2026 | 314.75 Mn |
| Dec 31, 2025 | 343.27 Mn |
| Sep 30, 2025 | 352.58 Mn |
| Jun 30, 2025 | 383.21 Mn |
| Mar 31, 2025 | 371.29 Mn |
| Dec 31, 2024 | 413.82 Mn |
| Sep 30, 2024 | 201.94 Mn |
| Jun 30, 2024 | 191.41 Mn |
| Mar 31, 2024 | 156.70 Mn |
| Dec 31, 2023 | 190.26 Mn |
| Sep 30, 2023 | 192.86 Mn |
| Jun 30, 2023 | 197.74 Mn |
| Mar 31, 2023 | 197.19 Mn |
| Dec 31, 2022 | 215.48 Mn |
| Sep 30, 2022 | 223.50 Mn |
| Jun 30, 2022 | 234.94 Mn |
| Mar 31, 2022 | 240.75 Mn |
| Dec 31, 2021 | 67.41 Mn |
| Sep 30, 2021 | 59.57 Mn |